Millie Nelson, senior editor for Partnering and Investment at BioXconomy, sat down with HaemaLogiX CEO Chris Baldwin to unpack the Australian biotech’s transition from private promise to public potential as it prepares for an IPO. Baldwin reflects on the unexpected momentum behind the company’s precision immunotherapy pipeline, built around the novel KMA and LMA antigens, and why market transparency, investor accountability and clinical discipline are central to HaemaLogiX’s strategy as it moves toward Phase II inflection points.

Nelson’s piece situates HaemaLogiX within a wider wave of next‑generation oncology innovation, highlighting how companies like CuraCell are also redefining the path to market with platforms designed to deliver more targeted, scalable and immune‑preserving cancer therapies. Together, these emerging players illustrate a shift in how early‑stage biotechs are approaching public markets: not with hype, but with differentiated science, clear clinical rationale and a focus on mechanisms that can meaningfully change patient outcomes.

To read the full story on HaemaLogiX’s journey — and the market forces shaping its next chapter — access the complete article here.